Here’s the translation for that Vietnamese article:
COVID-19 treatment: A new potential drug is being tested in the laboratory
Du Mien • 29/02/20 19:56 612 views
Innovation Pharmceuticals said on Thursday it will soon bring the new coronavirus potential drug to a regional biosafety laboratory for testing.
This potential drug is Brilacidin, capable of treating COVID-19 caused by a new virus.
Massachusetts-based Innovation Pharmceuticals said it has signed an agreement with one of the nation's 12 biosafety laboratories based at the university, to study Brilacidin as a treatment. New virus, and plans to bring Brilacidin to the laboratory in the coming days. Specific information about this lab was not disclosed.
Laboratory scientists will evaluate the potential anti-viral and anti-inflammatory properties of Brilacidin to combat viral infections, including SARS-CoV-2, the virus that causes COVID-19.
This potential drug will be tested with a number of infections along with other antiviral drugs.
The test can be completed within weeks of receiving Brilacidin, Innovation said in a press release.
The company says Brilacidin is a versatile compound with a broad therapeutic potential under a new chemical class called defensin-mimetic. An Nature review article on coronavirus suggests that immunomodulators such as Brilacidin could be a promising treatment for viruses, including SARS-CoV-2, when combined with Other antiviral drugs ,.
“The basic theory is that once the viral load is reduced, the body's natural immune response can be strengthened by Brilacidin after adjuvant therapy, so it is able to combat coronavirus complications well. more, ”the company said in a statement earlier in the week.
Innovation is also exploring cooperation with a government-funded virology laboratory in Asia to test Brilacidin, and has submitted a preliminary summary of the potential of Brilacidin, as a treatment. new coronavirus for the Advanced Biomedical Research and Development Agency.
A variety of other drugs are being tested as the virus spreads to new countries daily. The first case in South America was confirmed by Brazil on Wednesday (February 26) and seven other countries confirmed the first cases.
Gilead Science Inc.'s Remdesivir has been promoted as one of the strongest candidates to treat the new virus. It is being tested in tests in China and the United States. Chinese researchers are also testing Lopinavir and Ritonavir, two drugs commonly used to treat HIV, syndrome of human immunodeficiency virus infection, as well as Ritonavir and Ganovo.
On Thursday (February 27), Ascletis Pharma Inc. said three patients were discharged after being treated with Ganovo and Ritonavir. Favipiravir, approved for the treatment of influenza in several countries, has been participating in clinical development for COVID-19 this month.
* Never borrow to invest.
